Bristol Myers Squibb Stock Remains Undervalued After Positive Data From Clinical Trials

by Trefis Team
+40.78%
Upside
56.32
Market
79.29
Trefis
BMY
Bristol Myers Squibb
Rate   |   votes   |   Share

[Updated: 6/11/2021] BMS Positive Data From Clinical Trials

The stock price of Bristol Myers Squibb (NYSE:BMY) has seen a 3% rise in yesterday’s trading session (Jun 10), after the company announced positive data from phase three clinical trials of Breyanzi as a second line treatment in adults with relapsed or refractory large B-cell lymphoma. Breyanzi is Bristol Myers Squibb’s chimeric antigen receptor T cell (CAR-T) therapy, which was first approved by the U.S. FDA in Feb 2021 for the treatment of LBCL after two or more lines of systemic therapy. The recent development means Bristol Myers Squibb is all set to challenge Novartis and Gilead Lifesciences, that currently offer therapies for the treatment of LBCL.

In another development, the company announced positive data from phase two clinical trials of Reblozyl, for treatment of adults with non-transfusion dependent beta Thalassemia. Note that Reblozyl is already approved by the U.S. FDA for the treatment of Anemia in adults with beta Thalassemia who require regular red blood cell transfusions, and to treat Anemia in adults with lower-risk Myelodysplastic Syndromes (MDS).

While Breyanzi’s peak sales are estimated to be around $1.0 billion, that for Reblozyl are touted to be north of $2.0 billion. Label expansion for these drugs will likely result in higher sales going forward. Earlier in March 2021, Bristol Myers Squibb also secured approval for another CAR-T therapy – Abecma – for the treatment of relapsed multiple myeloma after four or more prior lines of therapy.

These developments will bode well for BMY stock going forward. BMY stock has risen by only 19% over the last one year, underperforming the broader markets, with the S&P 500 up 32%. This can partly be attributed to lower than estimated Q1 results, and weak sales for the company’s blockbuster drug – Opdivo. However, we continue to believe that BMY stock is undervalued. Going by our Bristol Myers Squibb Valuation of $80, based on expected adjusted EPS of $7.55 and a P/E multiple of 11x for 2021, there is over 18% upside potential from the current levels of around $67.

 

[Updated: 4/30/2021] BMY Stock Falls Post Q1

The stock price of Bristol Myers Squibb (NYSE:BMY) has seen a 5% drop over the last five trading days, after the company announced its Q1 results, which were slightly below the street estimates. Bristol’s Q1 revenue of $11.1 billion was largely in-line with the consensus estimates, while its adjusted EPS of $1.74 per share was short of the $1.82 consensus estimate. The results were impacted by Covid-19 to some extent and we believe that the company will likely see strong sales growth over the coming quarters, led by market share gains for Eliquis, and recent approvals boding well for Opdivo and Yervoy.

That said, the investors weren’t happy with Bristol’s Q1 performance and the stock plunged 5% in a single trading session, post the earnings announcement. Now that half of the U.S. population has received at least one dose of vaccine, the economy is expected to open up gradually, signaling improvement for Bristol stock over the coming quarters.

Going by historical performance, there is a 62% chance of a rise in BMY stock over the next month. Out of 116 instances in the last ten years that BMY stock saw a five-day decline of 5.2% or more, 72 of them resulted in BMY stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 72 out of 116, or about a 62% chance of gain in BMY stock over the coming month. Furthermore, Bristol has kept its adjusted earnings guidance unchanged for the full year, and we also maintain Bristol Myers Squibb’s Valuation of $80, based on an EPS estimate of $7.55 and a P/E multiple of 11x in 2021, reflecting a 26% premium to the current market price of around $63.

At the current market price of $63, BMY stock is now trading at just 8x its 2021 EPS estimate of $7.55. The 8x figure compares with levels of over 13x seen in 2018 and 2019, and a 10x figure seen as recently as late 2020. We continue to believe that BMY stock is undervalued and it can offer high returns going forward.

[Updated: 3/29/2021] BMY CAR-T Approval

The U.S. FDA has approved Abecma, a CAR-T (chimeric antigen receptor T cells) cell immunotherapy for the treatment of relapsed multiple myeloma after four or more prior lines of therapy. Abecma was being developed by Bristol Myers Squibb (NYSE:BMY) and bluebird bio Inc. CAR-T therapy refers to extraction of a patient’s own T cells, which are then genetically modified and infused back into the patient’s body. These T-Cells target and destroy any abnormal cells, including cancer cells. This is an important win for Bristol Myers Squibb and bluebird bio, given that the CAR-T therapy is expected to grow at a massive 45% CAGR over the next ten years. Many large pharmaceutical companies, including Bristol Myers Squibb, are working on CAR-T therapies. That said, the recent approval marks the only approved CAR-T therapy for the treatment of multiple myeloma. The stock prices of both Bristol Myers Squibb and bluebird bio are expected to see an uptick post this announcement.

Last week, we also discussed how BMY’s stock looks undervalued at $63, given that multiple positive triggers are expected in the near term, including the FDA approvals. After the multiple myeloma CAR-T therapy approval, eyes will now be on the FDA’s decision regarding  Opdivo’s use for additional indications, as well as Zeposia in ulcerative colitis. We continue to believe that BMY stock is undervalued currently, given the low P/E multiple of under 10x it currently trades at, compared to levels north of 13x seen over the recent years. Our dashboard, ‘What Factors Drove 21% Change In Bristol Myers Squibb Stock between 2018 and now?‘, has the underlying numbers.

[Updated: 3/26/2021] BMY Stock Looks Undervalued At $63

Bristol Myers Squibb (NYSE: BMY) looks very attractive at current levels of $63, as it is up only 40% from the levels it was at on March 23, 2020, when broader markets made a bottom due to the spread of Covid-19. This marks an underperformance compared to the S&P which has moved 75% since its March 2020 lows, with the resumption of economic activities as lockdowns are gradually lifted and vaccination programs have been initiated in multiple countries. This underperformance can primarily be attributed to investors concerns over the long term growth of the company. The company’s largest drug – Revlimid – which garnered $12 billion in 2020 sales, will lose its market exclusivity next year, implying a decline in sales, as generics gain market share. However, we believe that the stock is undervalued at the current levels of $63. Our dashboard, ‘What Factors Drove 21% Change In Bristol Myers Squibb Stock between 2018 and now?‘, has the underlying numbers.

Now, the company has given a guidance of low to mid-single-digit top-line expansion through 2025, which we believe to be conservative. Note that Bristol Myers Squibb has already entered into agreements with multiple companies, including Dr. Reddy’s Laboratories, Natco Pharma, and Alvogen to launch their generic version of Revlimid in limited volume post March 2022. The agreement with Dr. Reddy’s, for instance, will allow the Indian pharmaceutical company to sell its generic version without any volume limit only after January 2026. This essentially implies that Revlimid sales will not see a sharp drop in the first year of patent expiry. In fact, we estimate $10 billion in sales from Revlimid in 2025, post which, it will likely see a sharp decline. As we look forward, there are multiple positive triggers expected for the company. The FDA is expected to review Bristol Myers Squibb’s Opdivo for additional indications and Zeposia for treating ulcerative colitis. Note that Zeposia’s peak sales could be north of $5 billion, if it manages to secure regulatory approvals for ulcerative colitis and inflammatory bowel disease. In March 2020, Zeposia secured its first regulatory approval for relapsing forms of Multiple Sclerosis.

Not to forget, Eliquis, Bristol Myers Squibb’s oral blood thinner, which has added over $1 billion in incremental sales each year since 2014, a trend which now appears will continue for a few more years. In August 2020, a U.S. district court upheld the patents for Eliquis, with composition of matter patent expiring in 2026 and a formulation patent stretching out to 2031. This implies that Eliquis’ peak sales can be north of $13 billion in 2025, compared to $9 billion in 2020.

Overall, we believe that the company should do better than its guidance of low to mid-single-digit growth through 2025. The company is also sitting on cash of around $16 billion, and it won’t be surprising if it decided to consider more acquisitions to further boost its pipeline.

Lastly, let us look at the current valuation. At the current price of $63, BMY stock is trading at 8x its estimated 2021 adjusted earnings of $7.50 per share. This compares with levels of 15x seen in 2017, and over 10x seen in 2018 and 2019. If we look at some of the other pharmaceutical companies, J&J trades at 17x, Merck at 12x, Pfizer at 11x, and Eli Lilly at 22x forward annual earnings. This strengthens our view that BMY stock is undervalued at current levels, compared to both its own historical levels, as well as compared to its peers.

[Updated: 11/30/2020] BMY Stock Performance

We believe that Bristol Myers Squibb stock (NYSE: BMY) is a good buying opportunity at the present time. BMY stock trades near $63 currently and it is, in fact, down 6% from its pre-Covid high of $67 in February 2020 – just before the coronavirus pandemic hit the world. BMY stock has rallied over 35% since its March lows of $46, compared to a 63% gains for S&P 500. The underperformance can partly be attributed to the weaker than estimated sales of its blockbuster drug – Opdivo. That said, the company’s overall Q3 performance was better than street estimates, and now with economies opening up, the company will likely see improved sales growth and margin expansion, driving the stock higher from here, in our view. Our conclusion is based on our comparative analysis of Bristol Myers Squibb stock performance during the current financial crisis with that during the 2008 recession in our interactive dashboard.

2020 Coronavirus Crisis

Timeline of 2020 Crisis So Far:

  • 12/12/2019: Coronavirus cases first reported in China
  • 1/31/2020: WHO declares a global health emergency.
  • 2/19/2020: Signs of effective containment in China and hopes of monetary easing by major central banks helps S&P 500 reach a record high
  • 3/23/2020: S&P 500 drops 34% from the peak level seen on Feb 19, as COVID-19 cases accelerate outside China. Doesn’t help that oil prices crash in mid-March amid Saudi-led price war
  • Since 3/24/2020: S&P 500 recovers 62% from the lows seen on Mar 23, as the Fed’s multi-billion dollar stimulus package suppresses near-term survival anxiety and infuses liquidity into the system.

In contrast, here is how BMY stock and the broader market fared during the 2007-08 crisis

Timeline of 2007-08 Crisis

  • 10/1/2007: Approximate pre-crisis peak in S&P 500 index
  • 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08)
  • 3/1/2009: Approximate bottoming out of S&P 500 index
  • 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008)

BMY and S&P 500 Performance Over 2007-08 Financial Crisis

BMY stock declined from levels of about $29 in September 2007 (pre-crisis peak) to levels of $18 in March 2009 (as the markets bottomed out), implying BMY stock lost 37%. It recovered post the 2008 crisis, rallying 37% to levels of $25 by January 2010. In comparison, the S&P 500 Index saw a decline of 51% from its peak in September 2007 to its bottom in March 2009, followed by a sharp recovery of 48% by January 2010.

Bristol Myers Squibb Company Fundamentals Over Recent Years Have Been Strong

Bristol Myers Squibb’s revenues increased from $19.4 billion in 2016 to $26.1 billion in 2019, due to market share gains for its anticoagulant – Eliquis, along with the partial contribution of Celgene, which was acquired in 2019. The company has also seen its Net Margins expand from 24.5% to 30.7% on an adjusted basis, aiding its EPS, which grew from $2.83 to $4.69 over the same period. More recently,  Bristol Myers Squibb garnered over $10.5 billion in sales, reflecting 75% growth y-o-y in Q3 2020. The growth primarily reflects the impact of the Celgene merger, along with continued uptick in Eliquis, which grew 9% to $2.1 billion, while Opdivo saw a decline of 2% with sales of $1.8 billion during the quarter. The slowdown in Opdivo’s sales growth was anticipated, amid Merck’s Keytruda gaining market share. Looking at the bottom line, the company reported adjusted EPS of $1.63, reflecting 39% y-o-y growth.

Does Bristol Myers Squibb Have Sufficient Cash Cushion To Meet Its Obligations Through The Coronavirus Crisis?

Bristol Myers Squibb’s total debt increased from $7 billion in 2016 to $45 billion at the end of Q3 2020 (primarily due to the Celgene acquisition), while its total cash increased from $9 billion to $22 billion over the same period. Bristol Myers Squibb generated $10 billion cash from operations in the first nine months of 2020. While the company’s debt levels are high, the company has enough liquidity cushion to weather the current crisis.

Conclusion

Phases of Covid-19 Crisis:

  • Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally
  • Late-March 2020 onward: Social distancing measures + lockdowns
  • April 2020: Fed stimulus suppresses near-term survival anxiety
  • May-June 2020: Recovery of demand, with gradual lifting of lockdowns – no panic anymore despite a steady increase in the number of cases
  • July-October 2020: After poor Q2 results, Q3 expectations were lukewarm, but continued improvement in demand, and progress with vaccine development buoyed market sentiment

As the global economy opens up and lockdowns are lifted in phases, consumer demand is expected to pick up. This could be reflected in the form of a pick-up in revenue toward the end of 2020, followed by revenue growth in 2021, boding well for the BMY stock in the near term. While BMY stock has 6% upside for it to recover to pre-Covid highs, we believe the stock could trend much higher than that in the near term.

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio to beat the market, with over 100% return since 2016, versus 55% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.

 

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!